SG11202010528XA - Combinations for treating cancer - Google Patents
Combinations for treating cancerInfo
- Publication number
- SG11202010528XA SG11202010528XA SG11202010528XA SG11202010528XA SG11202010528XA SG 11202010528X A SG11202010528X A SG 11202010528XA SG 11202010528X A SG11202010528X A SG 11202010528XA SG 11202010528X A SG11202010528X A SG 11202010528XA SG 11202010528X A SG11202010528X A SG 11202010528XA
- Authority
- SG
- Singapore
- Prior art keywords
- combinations
- treating cancer
- cancer
- treating
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862664356P | 2018-04-30 | 2018-04-30 | |
| PCT/IB2019/053491 WO2019211721A1 (en) | 2018-04-30 | 2019-04-29 | Combinations for treating cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202010528XA true SG11202010528XA (en) | 2020-11-27 |
Family
ID=66794041
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202010528XA SG11202010528XA (en) | 2018-04-30 | 2019-04-29 | Combinations for treating cancer |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20210030718A1 (en) |
| EP (1) | EP3787620A1 (en) |
| JP (1) | JP2021522246A (en) |
| KR (1) | KR20210005182A (en) |
| CN (1) | CN112040944A (en) |
| AU (1) | AU2019263026B2 (en) |
| BR (1) | BR112020022020A2 (en) |
| CA (1) | CA3097486A1 (en) |
| EA (1) | EA202092540A1 (en) |
| MA (1) | MA52499A (en) |
| MX (1) | MX2020011453A (en) |
| SG (1) | SG11202010528XA (en) |
| TW (1) | TW202014184A (en) |
| WO (1) | WO2019211721A1 (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2020381240C1 (en) * | 2019-11-04 | 2024-02-15 | Astrazeneca Ab | Therapeutic combinations of acalabrutinib and capivasertib to treat B-cell malignancies |
| JP2023510135A (en) * | 2019-12-18 | 2023-03-13 | ゼノ マネジメント，インコーポレイテッド | macrocyclic compound |
| CA3222269A1 (en) | 2021-06-11 | 2022-12-15 | Gilead Sciences, Inc. | Combination mcl-1 inhibitors with anti-cancer agents |
| TW202317200A (en) | 2021-06-11 | 2023-05-01 | 美商基利科學股份有限公司 | Combination mcl-1 inhibitors with anti-body drug conjugates |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3495368B1 (en) | 2011-07-19 | 2023-05-31 | Merck Sharp & Dohme B.V. | (s)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-2-methoxy-n-(pyridin-2-yl)benzamide as btk-inhibitor |
| MX2017001656A (en) * | 2014-08-08 | 2017-07-24 | Pharmacyclics Llc | Bruton's tyrosine kinase inhibitor combinations and uses thereof. |
| ME03729B (en) * | 2016-04-22 | 2021-01-20 | Astrazeneca Ab | Macrocyclic mcl1 inhibitors for treating cancer |
| CN107056786B (en) * | 2016-10-14 | 2019-05-07 | 苏州明锐医药科技有限公司 | Ah Ka replaces the preparation method of Buddhist nun |
-
2019
- 2019-03-05 TW TW108107170A patent/TW202014184A/en unknown
- 2019-04-29 WO PCT/IB2019/053491 patent/WO2019211721A1/en unknown
- 2019-04-29 EA EA202092540A patent/EA202092540A1/en unknown
- 2019-04-29 MA MA052499A patent/MA52499A/en unknown
- 2019-04-29 KR KR1020207034122A patent/KR20210005182A/en unknown
- 2019-04-29 BR BR112020022020-5A patent/BR112020022020A2/en unknown
- 2019-04-29 CN CN201980028857.5A patent/CN112040944A/en active Pending
- 2019-04-29 CA CA3097486A patent/CA3097486A1/en active Pending
- 2019-04-29 SG SG11202010528XA patent/SG11202010528XA/en unknown
- 2019-04-29 JP JP2020559437A patent/JP2021522246A/en not_active Withdrawn
- 2019-04-29 EP EP19729355.8A patent/EP3787620A1/en not_active Withdrawn
- 2019-04-29 US US17/047,931 patent/US20210030718A1/en not_active Abandoned
- 2019-04-29 MX MX2020011453A patent/MX2020011453A/en unknown
- 2019-04-29 AU AU2019263026A patent/AU2019263026B2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| JP2021522246A (en) | 2021-08-30 |
| EA202092540A1 (en) | 2021-03-17 |
| WO2019211721A1 (en) | 2019-11-07 |
| BR112020022020A2 (en) | 2021-02-02 |
| AU2019263026B2 (en) | 2022-06-30 |
| CA3097486A1 (en) | 2019-11-07 |
| TW202014184A (en) | 2020-04-16 |
| AU2019263026A1 (en) | 2020-12-17 |
| US20210030718A1 (en) | 2021-02-04 |
| KR20210005182A (en) | 2021-01-13 |
| MX2020011453A (en) | 2020-12-07 |
| EP3787620A1 (en) | 2021-03-10 |
| MA52499A (en) | 2021-04-14 |
| CN112040944A (en) | 2020-12-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL270720A (en) | Combination therapies for treating cancer | |
| EP3641770A4 (en) | Methods for treating cancer | |
| IL260443B (en) | Anti-egfr combinations for treating tumors | |
| IL260444B (en) | Anti-her2 combinations for treating tumors | |
| IL255060A0 (en) | Combination therapy for treating cancer | |
| IL282663A (en) | Bt1718 for use in treating cancer | |
| IL273395A (en) | Combination therapies for treating cancer | |
| EP3678663A4 (en) | Combination therapy for treating cancer | |
| PT3576740T (en) | Cancer treatment | |
| IL287907A (en) | Methods for treating cancer | |
| IL277861A (en) | Axl-specific antibodies for cancer treatment | |
| SG11202010528XA (en) | Combinations for treating cancer | |
| EP3892282A4 (en) | Combination for treating cancer | |
| IL268416A (en) | Pharmaceutical combinations for treating cancer | |
| GB201903546D0 (en) | Cancer treatment | |
| GB201820660D0 (en) | Cancer treatments | |
| GB201706451D0 (en) | Cancer treatment | |
| IL287652A (en) | Cancer treatment | |
| IL282093A (en) | Combination therapy for cancer | |
| IL285466A (en) | Cancer treatment | |
| GB201800733D0 (en) | Cancer | |
| IL274626A (en) | Cancer treatment | |
| EP3894561A4 (en) | Methods for treating cancer | |
| GB201909468D0 (en) | Compounds for treating cancer | |
| IL268463A (en) | Cancer treatment |